Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Omniscan
Synonyms :
Acide gadopentetique, ácido gadopentético, Acidum gadopenteticum, Gadolinium diethylenetriamine pentaacetic acid, Gadolinium DTPA, Gadopentetate, gadopentetic acid
Class :
Diagnostic aid (contrast medium, NMR-tonography), Contrast media, Magnetic resonance imaging contrast media
Brand Name :
Omniscan
Synonyms :
Acide gadopentetique, ácido gadopentético, Acidum gadopenteticum, Gadolinium diethylenetriamine pentaacetic acid, Gadolinium DTPA, Gadopentetate, gadopentetic acid
Class :
Diagnostic aid (contrast medium, NMR-tonography), Contrast media, Magnetic resonance imaging contrast media
Dosage Forms & StrengthsÂ
Injectable solutionÂ
469.01 mg/mLÂ
Gadopentetic Acid is particularly indicated in cases like radiological contrast agents, arthrography, and correction of severe hypokalaemia
The usual recommended dose is 0.2 mL/kg via IV administration
Not to exceed 10 ml/min
For spinal and cranial imaging, the required dose is 0.4-0.6 mL/kg, which can be increased to 0.2 ml/kg for 30 minutes
Dose Adjustments
Renal dose adjustment
Severe: Not recommended (GFR <30 mL/min/1.73 m2)
Safety and efficacy are not seen in pediatricsÂ
Refer to the adult dosingÂ
gadopentetic acid could potentially decrease the excretion rate of abacavir, leading to a higher serum level
the excretion rate of gadopentetic acid may be reduced by aceclofenac, resulting in a higher serum level
gadopentetic acid may decrease the excretion rate of acemetacin, potentially leading to a higher serum level
the excretion rate of gadopentetic acid may be decreased by acetaminophen, causing a higher serum level
gadopentetic acid may decrease the excretion rate of bacitracin, potentially resulting in a higher serum level
the excretion rate of gadopentetic acid may be decreased by baclofen, leading to a higher serum level
gadopentetic acid may decrease the excretion rate of balsalazide, potentially resulting in a higher serum level
the excretion rate of baricitinib may be decreased by gadopentetic acid, leading to a higher serum level
gadopentetic acid may decrease the excretion rate of warfarin, potentially resulting in a higher serum level
the excretion rate of gadopentetic acid may be decreased by zaleplon, potentially leading to a higher serum level
gadopentetic acid may decrease the excretion rate of zanamivir, potentially resulting in a higher serum level
the excretion rate of gadopentetic acid may be increased by zonisamide, potentially leading to a lower serum level and a potential reduction in efficacy
Actions and Spectrum:Â
Actions:Â
Gadopentetic acid, commonly employed as a contrast agent in medical imaging, primarily exerts its action by interacting with the magnetic resonance imaging (MRI) process. It enhances the visibility of specific tissues and blood vessels in MRI scans, altering the magnetic properties of surrounding tissues and resulting in improved contrast between different structures.
This contrast enhancement is achieved through the inclusion of gadolinium, a paramagnetic substance, in gadopentetic acid. When introduced into the body, gadolinium enhances magnetic resonance signals, increasing the contrast in the images produced during an MRI. Gadopentetic acid demonstrates a tendency to accumulate in particular tissues and blood vessels, thereby improving the visualization of these areas during the imaging process.
As a diagnostic aid, it assists healthcare professionals in diagnosing and evaluating various medical conditions, including abnormalities in the brain, spine, and vascular system. Following intravenous administration, gadopentetic acid distributes throughout the vascular system, contributing to its capability to highlight blood vessels and specific tissues during imaging.Â
Spectrum:Â
Contrast agents, such as gadopentetic acid, are not formulated to selectively target specific biological activities or processes within the body. Rather, their role lies in enhancing the contrast in imaging.Â
The fundamental objective of gadopentetic acid is to enhance the visibility of specific tissues and blood vessels in the context of an MRI scan. This enhancement is facilitated by gadolinium, a paramagnetic substance present in gadopentetic acid. Upon introduction into the body, gadolinium amplifies the magnetic resonance signals, thereby augmenting the contrast observed in the resultant MRI images.Â
Frequency not definedÂ
HypotensionÂ
AllergyÂ
ConvulsionsÂ
Renal impairmentÂ
WeaknessÂ
VasodilationÂ
DizzinessÂ
FeverÂ
HeadacheÂ
ChillsÂ
VomitingÂ
NauseaÂ
Allergic reactionsÂ
TirednessÂ
AgitationÂ
SyncopeÂ
Black Box Warning:Â
The medication should be avoided in pregnant women and individuals with kidney dysfunction.Â
Contraindication/Caution:Â
ContraindicationsÂ
CautionsÂ
Pregnancy consideration:Â Â
No data is available regarding the administration of the drug during pregnancy.Â
Breastfeeding warnings:Â Â
No data is available regarding the excretion of drug in breast milk.Â
Pregnancy category: CÂ
Category A: well-controlled and satisfactory studies show no risk to the fetus in the first or later trimester.Â
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.   Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: No data is available for the drug under this category.Â
Pharmacology:Â
Pharmacodynamics:Â
N/AÂ
Pharmacokinetics:Â
AbsorptionÂ
N/AÂ
DistributionÂ
Vd = 266+-43 mL/kgÂ
MetabolismÂ
N/AÂ
Elimination and ExcretionÂ
The half-life is 16+-0.13 hoursÂ
Renal excretion of the drug is 90%Â
Administration:Â
Gadopentetic acid, commonly recognized by the brand name Omniscan, is typically delivered through injection to enhance contrast in magnetic resonance imaging (MRI). The administration process involves the following steps:Â
Healthcare professionals must take into account the patient’s medical history, allergies, and current health status before administering gadopentetic acid. Additionally, patients should communicate any pre-existing conditions, allergies, or medications they are taking to their healthcare providers.Â
As with any medical procedure, the administration of gadopentetic acid should be supervised by qualified healthcare professionals, and patients should adhere to the guidance provided by their healthcare team.Â
Patient information leafletÂ
Generic Name: gadopentetic acidÂ
Pronounced: GAD-oh-pen-TEH-tik AS-idÂ
Why do we use gadopentetic acid?Â
Gadopentetic acid serves as a contrast agent in medical imaging, specifically in magnetic resonance imaging (MRI). Its principal role is to heighten the visibility of particular tissues and blood vessels in the course of an MRI scan.
This enhancement of contrast is essential for acquiring more detailed and lucid images, thereby supporting healthcare professionals in diagnosing and evaluating a range of medical conditions.
By augmenting the contrast in MRI images, gadopentetic acid facilitates the identification of abnormalities in structures like the brain, spine, and vascular system. As an indispensable tool in diagnostic imaging, it furnishes valuable information for medical assessments without necessitating invasive procedures.Â